The Progress and Prospective of Computer-aided Antibody Design

Antibody has been widely utilized, generating enormous economic and social benefits. In the process of research and development, the use of antibody should be further optimized and reformed. However, the traditional transformation methods are blind, time-consuming with low success rates. Thereby a new method of rational transformation emerges as the times require—computer-aided antibody design & engineering.

Overview of Computer-aided Antibody DesignWith the development of bioinformatics in recent years, computer-aided antibody design has become a popular approach that is more targeted, helping to save time, reduce costs and improve the success rate. Having gained enormous success in the past decades, the computer science and technology has almost infiltrated into every aspects of human life, with no exception to biomedical science. Benefiting from the progress of computer devices, like supercomputer, and the programming language for computational biology, scientists are able to achieve structural information with more details, which make it possible to have a look at the function and mechanisms of biological molecules like antibodies, but more importantly, to realize manufacturing molecules with desired functions. Creative Biolabs, as a leading biotech company focused on antibody engineering has launched the comprehensive computer-aided antibody development platform, named PreciAb™, made up of high-end techniques and proprietary algorithms for designing specific antibodies.

Computer-aided Antibody TechnologiesThe technologies are variably applied according to the ultimate purpose of antibody design and manufacturing.

Epitope-specific Antibody DesignThe package made up of Antibody Structure Modelling, Antibody-antigen Complex Analysis, Computer-aided Affinity Maturation, Antibody Structure Determination, and Experimental Validation adopts the most up-to-date technologies. Specifically speaking, the homology modeling and antibody initio (or de novo) modeling are used in the preliminary stage, paving the way for further step operation. Facilitated with the advanced computer docking protocol embedding the latest knowledge of antibody-antigen interactions and conformational flexibility of the CDR region, the complex components get analyzed comprehensively. PreciAb™ platform involves in every step of the designing process, including the affinity maturation and structure determination of antibody.

Structure-based Antibody ReformattingIn silico technologies are applied for the antibody reformatting operations in Creative Biolabs, including homology modeling, molecular dynamics simulation, in-house algorithm, antibody molecule model analysis, which make it possible to detect what residues are shaping the antibody feature, and then make mutation on the residues to change antibody nature on their variable region.

To conclude, the computer-aided antibody design has the potential to be the assistant of antibody modification, especially for therapeutic antibodies. It is believed that with the further development of biological information, computer-aided antibody design will gain a more crucial place in the medical therapeutic field in the future. With Creative Biolabs’s comprehensive technology platform, designing and engineering novel antibodies with desired therapeutic properties will break through the problems that hinder the pharmaceutical industry. For details accordingly, please visit https://www.creative-biolabs.com/preciab/.

About the Company

As a leading bio-tech company, Creative Biolabs bends efforts for antibody design and engineering in all fields, covering research, diagnosis, and therapy. Designing and engineering novel antibodies with desired therapeutic properties is now available based upon the comprehensive PreciAb™ platform, through customizing the service according to the specific requirements from the customers.

I’m a fan of biotechnology who sometimes shares articles regarding antibody, therapeutics, antibody engineering technologies on site.